about
Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy.An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample.Consensus conference on the management of tumor lysis syndrome.[Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].Cost of illness in patients with multiple myeloma in Italy: the CoMiM study.Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS).Treating Verse Non-Treating Obsturictive Sleep Apnea in Italy and France: A Markov Model-Based Cost-Effectiveness Analysis.An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizonCost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) studyA Health Technology-Related Cost Description Concerning Italian Ibd Centres Dealing With Crohn's Disease Results From Sole StudyHealth-Related Quality of Life in Italian Patients With Moderate and Severe Crohn's Disease: Interim Results from the Sole StudySubcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysisEconomic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1bHealthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-upCorrigendum to "Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up" [Respir. Med. 153 (2019) 68-75]
P50
Q36722724-72F0E9C1-91B2-40EB-BE09-F03206A74A1AQ36776918-239BE852-6C48-427D-8E18-2843B5591706Q37016870-35FF0496-69F7-40A1-9A1C-560084DA4912Q37288189-ADDCA215-9060-40E0-A2BB-79C9EBC0B035Q42976801-DE8E9116-FC84-428E-A918-2447CE816DFFQ46754008-59708F3B-541B-4852-8F3D-4D7873A0FA93Q46880420-E4EFC42F-19B6-41DF-BEA5-44C27B2AEB52Q48019402-6EAB5AE1-9A02-4B4B-ABF9-00B5E4FEA769Q53910582-AF219FFA-8157-4863-B987-2CA19F31BE83Q56977271-6E27706A-403A-4F20-8F60-B89B34060E7BQ61633547-C8811A04-966D-42EA-B513-506C1F94DCA9Q61633548-B49159B0-E0C1-4D7C-BFBB-94D148CA70C9Q61633549-7E32145F-1D19-46DA-8A90-4B40449FD238Q61633550-6CDE8043-8AE9-45A0-8E2D-7E310C11AE53Q61633551-0D5F1578-55B3-489E-AA80-3564BE277A27Q92587782-F44F0F2F-7618-435A-8BF1-156AC1076AC4Q92769836-10887095-0255-4FD2-B17D-4B48D9CD3C47
P50
description
researcher ORCID ID = 0000-0003-4795-1834
@en
wetenschapper
@nl
name
C Lazzaro
@nl
Carlo Lazzaro
@en
Carlo Lazzaro
@es
type
label
C Lazzaro
@nl
Carlo Lazzaro
@en
Carlo Lazzaro
@es
altLabel
C Lazzaro
@en
prefLabel
C Lazzaro
@nl
Carlo Lazzaro
@en
Carlo Lazzaro
@es
P106
P21
P31
P496
0000-0003-4795-1834